Pyxis Oncology, Inc. $PYXS Shares Sold by American Century Companies Inc.

American Century Companies Inc. cut its stake in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) by 91.2% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 26,353 shares of the company's stock after selling 273,584 shares during the period. American Century Companies Inc.'s holdings in Pyxis Oncology were worth $26,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in PYXS. Millennium Management LLC increased its holdings in shares of Pyxis Oncology by 53.8% in the 4th quarter. Millennium Management LLC now owns 2,980,906 shares of the company's stock valued at $4,650,000 after acquiring an additional 1,043,228 shares during the last quarter. Ridgeback Capital Investments L.P. bought a new position in Pyxis Oncology during the 4th quarter worth $560,000. Pier 88 Investment Partners LLC grew its stake in Pyxis Oncology by 296.6% during the 1st quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company's stock worth $383,000 after buying an additional 292,370 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its stake in Pyxis Oncology by 57.2% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 601,940 shares of the company's stock worth $939,000 after buying an additional 219,100 shares during the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Pyxis Oncology during the 4th quarter worth $228,000. 39.09% of the stock is currently owned by institutional investors.

Pyxis Oncology Stock Performance

Shares of NASDAQ:PYXS traded down $0.13 on Tuesday, hitting $1.83. The company's stock had a trading volume of 951,912 shares, compared to its average volume of 699,286. Pyxis Oncology, Inc. has a 12 month low of $0.83 and a 12 month high of $5.39. The company has a market capitalization of $113.50 million, a price-to-earnings ratio of -1.14 and a beta of 1.14. The stock's 50-day moving average is $1.23 and its two-hundred day moving average is $1.16.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.06. The business had revenue of $2.82 million during the quarter. Equities analysts expect that Pyxis Oncology, Inc. will post -1.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PYXS has been the subject of a number of recent research reports. Wall Street Zen upgraded Pyxis Oncology from a "sell" rating to a "hold" rating in a research note on Sunday, August 24th. HC Wainwright restated a "buy" rating and set a $5.00 price objective on shares of Pyxis Oncology in a research note on Tuesday, August 19th. Guggenheim initiated coverage on Pyxis Oncology in a research note on Wednesday, September 3rd. They set a "buy" rating and a $5.00 price objective for the company. Finally, Zacks Research upgraded Pyxis Oncology from a "strong sell" rating to a "hold" rating in a research note on Monday, August 18th. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.75.

Pyxis Oncology Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.